Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era

Published: September 2016
No. of Pages: 135
Single User License: US $ 3500
Corporate User License: US $ 10500

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chronic Pain (2016) are definite steps taken by FDA in last two years for creating “Abuse Deterrent Era” in a short span to stop opioid abuse and reversing opioid epidemic in USA.  There were around 18,893deaths involving prescription of opioids in the United States in 2014 which was up 16% from 2013 as per NCHS (National Center for Health Statistics).

Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxaydo) and are expected to provide improvements over existing formulations for abuse deterrent purpose.  But they have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse  (through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant value to create “Abuse Deterrent Era” in the coming time.

Around 20 plus Abuse Deterrent Formulations of opioids are in the pipeline and most of them are ER formulations which use different AD tech platform to make its ADF.  Amongst these pipeline ADF drugs, 6 are of Hydrocodone, 8 are of Morphine and 6 are of Oxycodone based ADF formulations.  

New NCEs targeting Opioids receptor are in pipeline which reduces Opioids abuse by its MoA (slow rate of entry in Brain) and may have potential to deal with reducing opioid abuse through restricting oral intake in coming years.  

US Opioids market is of $8b in size and of which extended release formulations contribute 50%.  ADF ER formulations and its generic versions & New NCEs targeting Opioid receptor will drive the growth of opioid market in US and Europe in coming years.

In this report, we have discussed a number of novel delivery technologies employed in the formulating abuse deterrent product, technologies employed in enhancing patient compliances, emerging novel mechanisms and late stage pipeline drugs in the management of pain.

Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,…) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for  pain management has potential to reduce opioids use in future to treat pain. While TRKA receptor antagonist, NAV1.7 sodium channel modulator inhibitor and angiotension II antagonist are few new MoA which has promising drug in clinical development for moderate to severe pain management.

Companies mentioned:

  • AbbVie
  • AcelRx pharma
  • Acorda Therapeutics
  • Actavis
  • Acura Pharma
  • Acorda Therapeutics
  • Altus formulations
  • Alkermes
  • Algiax Pharmaceuticals
  • Amorsa Therapeutics
  • AnGes
  • AstraZeneca
  • Balerna
  • Biogen
  • BioDelivery Sciences International Inc
  • Biopharma
  • Cara Therapeutics
  • Catalent
  • Charleston
  • Celltech
  • Collegium Pharma
  • Convergence
  • Columbia Labs
  • Convatech
  • Daiichi Sankyo
  • Daewoong
  • Depomed
  • Durect
  • Egalet
  • Eli Lilly
  • Elite Pharma
  • Endo
  • Ensyce Bioscience
  • EpiCept
  • Flamel Technologies
  • Flexion Therapeutics
  • Forest
  • Glenmark
  • Grunenthal
  • GlaxoSmithKline
  • GW Pharma
  • Immune Pharmaceuticals
  • Impax Pharmaceuticals
  • Inspirion
  • Intelli Pharmaceutics
  • IRX Therapeutics
  • Johnson and Johnson
  • KemPharm
  • Kineta
  • Kunwha Pharmaceutical
  • Medallion Therapeutics
  • Mallinckrodt
  • Nektar
  • Novartis
  • Noven
  • Orbis Biosciences
  • Orexo
  • Otsuka
  • Pain Therapeutics
  • Pfizer
  • ProPharma
  • Purdue
  • Recro pharma
  • Relmada Therapeutics
  • Reckitt Benckiser pharmaceutical
  • Signature Therapeutics
  • Spinifex pharma
  • SPR Therapeutics
  • Strativa
  • Teikoku
  • Teva
  • Tesa Labtec GmpH
  • Trevena Inc
  • Tris Pharma
  • Valeant
  • ViroMed
  • Wooddiff Lake
  • Xenon Pharma
  • XenoPort

Published By: MP Advisors
Product Code: MP Advisors43

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: